Clinical Trial Update: MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma [Phase 2]

View source ↗

Summary

MEKTOVI (binimetinib) is being studied in a Phase 2 pediatric trial for adamantinomatous craniopharyngioma, with recruitment currently ongoing. The study is spo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adamantinomatous Craniopharyngioma

Drugs mentioned

• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma | Phase 2 | Status: RECRUITING